TGW101
Advanced Solid Tumors (TAG72+)
Key Facts
About Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a clinical-stage biotech pioneering a Nobel Prize-inspired Click-to-Release platform to revolutionize targeted cancer therapies. Its core technology uses a bioorthogonal chemical reaction triggered by an administered molecule to precisely release drug payloads at the tumor site, aiming to overcome key limitations of ADCs and radiopharmaceuticals. The company has two clinical-stage assets: TGW101, an ADC targeting the non-internalizing antigen TAG72 in solid tumors (Phase 1), and TGW211, a HER2-directed radioimmunoconjugate (Phase 0/1). Backed by a seasoned team and leading life science investors, Tagworks is positioned to expand the targetable landscape in oncology with its innovative prodrug activation approach.
View full company profile